SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.

• Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY
  Management is scheduled to participate in a fireside chat on Monday, September 8^h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time.

• Q3 Investor Summit Group Virtual Conference
  Management is scheduled to present on Tuesday, September 16^th at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time and will host 1x1 meetings on Wednesday, September 17^th.

Interested parties may access live and archived webcasts of the presentations on the “Investors” section of the company website at: www.nautilus.bio.

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.